药物对比
Canagliflozin vs Sotagliflozin
比较Canagliflozin（Invokana）与Sotagliflozin（Inpefa）治疗2型糖尿病和心力衰竭。SGLT2抑制剂与SGLT1/2双重抑制剂：机制、适应证、疗效及安全性差异。
此页面暂无可用的对比维度。
临床背景
This comparison is triggered when selecting an SGLT inhibitor for type 2 diabetes patients who also have heart failure or elevated cardiovascular risk.
结论
Both provide meaningful cardiorenal protection but neither is superior overall; selection hinges on approved uses, comorbidities, and individual factors.
全部药物对比